4:46 PM
 | 
Nov 14, 2012
 |  BC Extra  |  Clinical News

ViiV reports additional Phase III data for dolutegravir

ViiV Healthcare Ltd. reported that the addition of twice-daily 50 mg dolutegravir to patients' current failing integrase inhibitor-containing regimen significantly reduced mean HIV-1 RNA levels from baseline to day eight, a co-primary endpoint, by 1.4 log10 copies/mL (p<0.001) in the Phase III VIKING-3 trial to treat HIV-1 infection...

Read the full 223 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >